Previous 10 | Next 10 |
– Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma – – Enhanced activity (40% CR rate, 70% ORR) observed in AITL patients with KIR mutations, a CXCL pathway-associated biomarker – ...
SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Off...
Kura Oncology ( KURA ) is a biotech that should be on everyone's radar. That's because it has an upcoming catalyst that could be a game changer. It has already reported results from its phase 2 study using Tipifarnib to treat patients with relapsed/refractory Peripheral T-cell lymphoma ((PTC...
SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Off...
Kura Oncology, Inc. (KURA) Q3 2019 Earnings Conference Call November 05, 2019, 04:30 PM ET Company Participants Pete De Spain - VP, IR Troy Wilson - President & CEO Marc Grasso - CFO Antonio Gualberto - Chief Medical Officer & Head of Development Conference Call Part...
SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that an abstract related to the Company’s lead drug candidate, ti...
Image source: The Motley Fool. Kura Oncology, Inc. (NASDAQ: KURA) Q3 2019 Earnings Call Nov 5, 2019 , 4:30 p.m. ET Operator Continue reading
Kura Oncology (NASDAQ: KURA ): Q3 GAAP EPS of -$0.36 beats by $0.02 . More news on: Kura Oncology, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
– Updated data from Phase 2 trial of tipifarnib in HRAS mutant HNSCC support enrichment strategy in ongoing registration-directed trial – – Data from Phase 2 trial of tipifarnib in AITL accepted for oral presentation at ASH 2019 – – Initiation of firs...
SAN DIEGO, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report third quarter 2019 financial results after the close...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 22:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 08:15:04 ET H.C. Wainwright analyst issues BUY recommendation for KURA on June 25, 2024 06:44AM ET. The previous analyst recommendation was Buy. KURA was trading at $21.08 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
– Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes – – Kura advancing multiple, next-generation menin inhibitor drug candidates targeting diabetes and other metabolic diseases ...